<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20161220031496N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-04-14</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of right atrial appendage valve in TOF</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of mid-term results of pulmonary valve reconstruction using right atrial appendage among children with tetralogy of Fallot</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-04-30</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>20</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/62709</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Condition 1: Tetralogy Fallot. Condition 2: Pulmonary valve regurgitation. Condition 3: Pulmonary valve stenosis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: For the first time the pulmonary valve repair in children with tetralogy of Fallot, we make an autologous valve for the patients and it is assumed that this valve grows with age and does not suffer from stenosis and insufficiency, and this surgical method Improves patients' lives. We hope that in this study we will obtain acceptable results from the function of this new valve as a pulmonary valve. This valve is made of the patient's right atrium at the time of surgery. And the possibility of new pulmonary valve insufficiency and stenosis may decrease, and therefore right ventricular failure in these patients decreases, and the possibility of the need for pulmonary valve implantation in the coming years for these patients also decreases. The appendage is clamped and is cut over the clamp and kept in a saline solution. The right atrial stamp is closed by suturing in two layers, first a mattress row under the vascular clamp and then an over-and-over suture run after removing the clamp.  All the larger muscle bands are accurately excised to make the layers thinner and more pliable. The smaller muscle tissues are left in place to prevent accidental perforation of the cusps. The valve is now placed instead of the pulmonary valve, with the proximal end positioned at the annulus level and the distal end toward the pulmonary artery bifurcation. In cases with very short main pulmonary arteries, care should be taken not to obstruct the orifice of the right pulmonary artery by our valve tissue.20 patients will be operated with this method. Intervention 2: Control group: Children with tetralogy of Fallot who correspond to the intervention group in different conditions and we will operate on them with the conventional pulmonary transnnular patch method, will be studied as this group. In this surgical procedure that has been done in the world for years, we make an incision in the right ventricular outflow tract towards the pulmonary valve, which continues to the pulmonary artery. The gap is then covered with a pericardial patch. Therefore, the pulmonary valve loses its activity in this method and the patient suffers from pulmonary valve insufficiency. 20 patients will be operated with this conventional method.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The surgical procedure as well as all the echocardiographic and ECG data will be provided in detail.

When:
unlimited

To whom:
All cardiac surgeons and cardiologists in the world

Conditions:
To improve the surgery of tetralogy of Fallot

Where to obtain:
Apply by email to the scientific or general manager of this project

How to obtain:
After a written request by email from the applicants, it will be provided to them by the scientific manager

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammadreza Edraki</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Namazi Hospital- Zand Blvd</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7193613311</zip>
        <telephone>009836474332</telephone>
        <email>edrakimr@sums.ac.ir</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ahmadali Amirghofran</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faghihi Hospital- Zand Blvd</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7134846114</zip>
        <telephone>009832351087</telephone>
        <email>amirghofranaa@yahoo.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Fallot tetralogy patients whose pulmonary valve needs to be repaired
Fallot tetralogy patients who need insertion of a conduit
Fallot tetralogy patients who need a transannular patch</inclusion_criteria>
      <agemin>6 months</agemin>
      <agemax>2 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients with small right atrial appendage
Patients who have previously had heart surgery
Patient with conduction anomalies</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Q21.3</hc_code>
      <hc_code>I37.2</hc_code>
      <hc_code>I37.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Tetralogy of Fallot</hc_keyword>
      <hc_keyword>Nonrheumatic pulmonary valve stenosis with insufficiency</hc_keyword>
      <hc_keyword>Nonrheumatic pulmonary valve stenosis with insufficiency</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: For the first time the pulmonary valve repair in children with tetralogy of Fallot, we make an autologous valve for the patients and it is assumed that this valve grows with age and does not suffer from stenosis and insufficiency, and this surgical method Improves patients' lives. We hope that in this study we will obtain acceptable results from the function of this new valve as a pulmonary valve. This valve is made of the patient's right atrium at the time of surgery. And the possibility of new pulmonary valve insufficiency and stenosis may decrease, and therefore right ventricular failure in these patients decreases, and the possibility of the need for pulmonary valve implantation in the coming years for these patients also decreases. The appendage is clamped and is cut over the clamp and kept in a saline solution. The right atrial stamp is closed by suturing in two layers, first a mattress row under the vascular clamp and then an over-and-over suture run after removing the clamp.  All the larger muscle bands are accurately excised to make the layers thinner and more pliable. The smaller muscle tissues are left in place to prevent accidental perforation of the cusps. The valve is now placed instead of the pulmonary valve, with the proximal end positioned at the annulus level and the distal end toward the pulmonary artery bifurcation. In cases with very short main pulmonary arteries, care should be taken not to obstruct the orifice of the right pulmonary artery by our valve tissue.20 patients will be operated with this method.</i_keyword>
      <i_keyword>Control group: Children with tetralogy of Fallot who correspond to the intervention group in different conditions and we will operate on them with the conventional pulmonary transnnular patch method, will be studied as this group. In this surgical procedure that has been done in the world for years, we make an incision in the right ventricular outflow tract towards the pulmonary valve, which continues to the pulmonary artery. The gap is then covered with a pericardial patch. Therefore, the pulmonary valve loses its activity in this method and the patient suffers from pulmonary valve insufficiency. 20 patients will be operated with this conventional method.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Neo pulmonary valve stenosis. Timepoint: Q 6 months. Method of measurement: Transthoracic Echocardiography.</prim_outcome>
      <prim_outcome>Neo pulmonary valve stenosis. Timepoint: Q 6 months. Method of measurement: Transthoracic echocardiography.</prim_outcome>
      <prim_outcome>Possibility of conduction disturbances. Timepoint: Q 6 months. Method of measurement: ECG.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-04-06</approval_date>
        <contact_name>Shiraz University of Medical Sciences</contact_name>
        <contact_address>Zand Blvd Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
